| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13G · 4 securities · passive | ||||||
|
Research Alliance Corporation III
13G
RACC · G75226103
|
6.4% |
8/14/2026
Event 6/30/2026
|
||||
| TCG Crossover GP III, LLC | 6.4% | |||||
| TCG Crossover Fund III, L.P. | 6.4% | |||||
| Chen Yu | 6.4% | |||||
|
Entera Bio Ltd.
13G
ENTX · M40527109
|
7.1% |
8/4/2026
Event 7/28/2026
|
||||
| TCG Crossover GP III, LLC | 7.1% | |||||
| TCG Crossover Fund III, L.P. | 7.1% | |||||
| Chen Yu | 7.1% | |||||
|
Editas Medicine, Inc.
13G
EDIT · 28106W103
|
9.9% |
6/3/2026
Event 5/27/2026
|
||||
| TCG Crossover GP III, LLC | 9.9% | |||||
| TCG Crossover Fund III, L.P. | 9.9% | |||||
| Chen Yu | 9.9% | |||||
|
InflaRx N.V.
13G
IFRX · N44821101
|
9.8% |
5/12/2026
Event 5/7/2026
|
||||
| TCG Crossover GP III, LLC | 9.8% | |||||
| TCG Crossover Fund III, L.P. | 9.8% | |||||
| Chen Yu | 9.8% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.